CONWAY, Ark., Sept. 18, 2026 (GLOBE NEWSWIRE) — Home BancShares, Inc. (NYSE: HOMB) (“Home” or “the Company”), parent company of Centennial Bank (“Centennial”), today announced two recent performance recognitions. First, on September 9, 2026, Forbes published their “World’s Top Performing Banks” list, and HOMB ranked #5 in Mid-Size Banks. Banks were evaluated across four main dimensions: profitability, growth & earnings quality, capital & funding resilience and asset quality & efficiency. Eligible banks were segmented into six tiers based on their total assets and then the scores were assigned. HOMB is among Tier 4 (mid-size banks) which have $20-$50 billion in assets. This is a new ranking by Forbes, and it is predicated on objective financial data obtained through leading data providers, such as S&P Capital...

In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-‘749 achieved stabilization, few relapsed and more than one-fifth of participants receiving TEV-‘749 for ≥ 6 months met criteria for remission  Treatment switch analyses provide clinical insights into maintaining established therapeutic ranges of olanzapine when initiating TEV-‘749 from existing regimens Ahead of the Q4 FDA anticipated approval decision, the growing body of science around TEV-‘749 demonstrates Teva’s commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchisePARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...

New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD) in patients aged ≥55 years Across all four patient profiles, AUSTEDO® (deutetrabenazine) was most closely related to the attributes most valued by healthcare providers These findings from Teva detail specific healthcare provider preferences around tolerability and efficacy, while reinforcing the importance of treatment for TDPARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting...

New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world data also show that UZEDY decreased emergency room visits and hospitalizations, lowering overall healthcare resource utilization and delivering over $1,000 per patient per month in direct cost savings The breadth of clinical evidence presented highlights Teva’s ongoing commitment to evaluating how therapies perform in patients’ everyday lives to assist in improving routine care and reducing the burden of severe mental illnessPARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment...

CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner to engage with industry, investors and scientific leaders during a concentrated week in Boston TORONTO and HAIFA, Israel, Sept. 18, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a series of U.S. engagements across four major life sciences events taking place in Boston from September 22-25, 2026. The conferences will feature participants from across the global life sciences sector, including investors, scientists and representatives from leading pharmaceutical companies. As part of the Company’s business development and stakeholder-engagement activities in the U.S., Chief Executive Officer Dr. Lior Shaltiel will actively...

September 18th, 2026 DIAC : ‘’ Financial Report as at June 30th 2026’’ The financial Report as at June 30th 2026 is now available on the Mobilize Financial Services website www.mobilize-fs.com.AttachmentDIAC RFS H1 2026

HERNDON, Va., Sept. 18, 2026 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) today announced the successful closing of its $612.5 million Navient Private Education Loan Trust (NAVSL) 2026-A transaction, the company’s fourth student loan securitization of the year. NAVSL 2026-A represents Navient’s first securitization designed to support investment by investors subject to the European Union’s securitization regulation and the United Kingdom’s securitization regulatory framework. “Expanding access to our securitizations for investors operating under EU and UK regulatory frameworks reflects our ongoing commitment to the capital markets,” said Steve Hauber, chief financial officer of Navient. “We are pleased to structure this transaction with risk retention features designed to support these investors’ compliance needs while demonstrating...